Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Change in Account Payables (2023 - 2025)

Immunome (IMNM) has disclosed Change in Account Payables for 3 consecutive years, with -$2.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Account Payables fell 124.56% year-over-year to -$2.3 million, compared with a TTM value of -$9.2 million through Dec 2025, down 196.2%, and an annual FY2025 reading of -$9.2 million, down 196.2% over the prior year.
  • Change in Account Payables was -$2.3 million for Q4 2025 at Immunome, down from $1.9 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $9.3 million in Q4 2024 and bottomed at -$4.9 million in Q2 2025.
  • Average Change in Account Payables over 3 years is -$20500.0, with a median of -$355500.0 recorded in 2023.
  • The sharpest move saw Change in Account Payables skyrocketed 1465.24% in 2024, then crashed 15362.5% in 2025.
  • Year by year, Change in Account Payables stood at -$679000.0 in 2023, then surged by 1465.24% to $9.3 million in 2024, then crashed by 124.56% to -$2.3 million in 2025.
  • Business Quant data shows Change in Account Payables for IMNM at -$2.3 million in Q4 2025, $1.9 million in Q3 2025, and -$4.9 million in Q2 2025.